SCHEDULE: Kynam Capital Management Reports 9.96% Stake in CytomX Therapeutics

Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported beneficial ownership of 9.96% of CytomX Therapeutics' common stock as of June 30, 2026.

Summary

• Kynam Capital Management, LP, along with its general partner Kynam Capital Management GP, LLC, and Yue Tang, have filed a Schedule 13G amendment.
• This filing indicates a change in beneficial ownership of CytomX Therapeutics, Inc. common stock.
• The reporting persons collectively beneficially own 21,703,093 shares, representing 9.96% of the class of securities.
• The date of the event requiring this filing is June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new strategic or financial information.

Positives

• The filing clearly discloses a significant ownership stake (9.96%) by Kynam Capital Management, providing transparency to the market.
• The reporting persons have shared voting and dispositive power over the 21,703,093 shares, indicating a coordinated approach to their investment.

Negatives

• The filing does not provide any new financial results, strategic updates, or forward-looking guidance from CytomX Therapeutics.
• The aggregate amount beneficially owned is reported as 0 in row (9), which appears to be a discrepancy or specific reporting convention that requires further clarification, though the percentage ownership is clearly stated.

Risks

• The filing does not explicitly mention any new risks or challenges faced by CytomX Therapeutics.
• Potential risks for investors could include the possibility of further significant share sales by Kynam Capital Management, which could impact share price.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it is a disclosure of beneficial ownership.

Management Comments

• Yue Tang, as Managing Member for Kynam Capital Management, LP and Kynam Capital Management GP, LLC, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings are common in the biotechnology sector, often indicating active investment by institutional holders. This filing places Kynam Capital Management as a notable shareholder in CytomX Therapeutics.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant ownership stake, potentially influencing market perception and trading activity.
• Management of CytomX Therapeutics: Awareness of a substantial institutional investor's position.

Next Steps

• Kynam Capital Management will continue to hold and potentially manage its stake in CytomX Therapeutics.
• CytomX Therapeutics may continue its operations and strategic initiatives as previously disclosed in other filings.

Key Dates

Keywords

CytomX Therapeutics, Kynam Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Shareholder